Objective: The aim of the present study was to investigate the efficacy and safety of ipragliflozin treatment on glycemic control in patients with type 2 diabetes mellitus (T2DM).
Methods: We recruited 44 patients with T2DM, treated them with 50 mg/day of ipragliflozin for 12 weeks, and assessed several diabetic variables before and after treatment. We used stepwise multiple regression analysis to evaluate response to ipragliflozin in terms of changes in hemoglobin A1c (HbA1c) levels after therapy.
Results: Treatment with ipragliflozin for 12 weeks significantly decreased fasting glucose, HbA1c, and blood pressure levels without severe adverse events. The baseline HbA1c (β = -0.52, p < 0.01) and alanine aminotransferase (ALT) levels (β = -0.29, p = 0.03) were independently and significantly related to a decrease in HbA1c levels.
Conclusions: In patients with T2DM, ipragliflozin treatment improved glycemic control, and baseline HbA1c and ALT levels appeared to predict treatment response.